Global BipolarDisorder Treatment Market, By Drug Class (Antipsychotics, Antidepressants,Mood Stabilizers, and Anti-anxiety Drugs and Others), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),is estimated to be valued at US$ 7,288.3 million in 2019 and is expected toexhibit a CAGR of 5.2% over the forecast period (2019-2027), as highlighted ina new report published by Coherent Market Insights.
Governments and healthcareorganizations are supporting various clinical developmental stage companies andresearch organizations to develop novel drugs for the treatment of bipolardisorder, which is likely to drive the market growth over the forecast period.For instance, in January 2018, European Union’s Horizon 2020 Research andInnovation program awarded grant of US$ 8.8 million to R-Link, a cohort studyfor lithium initiation. The R-Link study has been initiated by researchers atCentre for Affective Disorders, Department of Psychological Medicine at theInstitute of Psychiatry, Psychology & Neuroscience, King’s College London.
Moreover, in June 2017, the IowaNeuroscience Institute announced that it will grant fund of US$ 150,000annually for five years to psychiatry research center (Department of Psychiatryin University of Iowa), in order to create a Bipolar Disorder Research Programof Excellence.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2605
Browse 27 Market Data Tables and26 Figures spread through 201 Pages and in-depth TOC on “Bipolar DisorderTreatment Market”- Global Forecast to 2027, by Drug Class (Antipsychotics,Antidepressants, Mood Stabilizers, and Anti-anxiety Drugs and Others), byDistribution Channel (Hospital Pharmacies, Retail Pharmacies, and OnlinePharmacies), and by Region (North America, Latin America, Europe, Asia Pacific,Middle East, and Africa).
Major players operating in thebipolar disorder treatment market are collaborating and partnering to focus onvarious operations ranging from research and development, manufacturing, salesand distribution, and others of bipolar disorder drugs, which is expected toboost the market growth over the forecast period. For instance, in February2016, Sound Pharmaceuticals (SPI) announced collaboration with University ofOxford, in order to develop novel treatment for bipolar disorder. Under thiscollaboration agreement, in November 2017, both the companies collaborativelyinitiated the Phase II clinical trial for SPI-1005 for the treatment ofpatients with bipolar disorder. SPI-1005 is an oral drug containing ebselen,which mimics and induces the activity of Glutathione Peroxidase (GPx) in theinner ear and brain. The study was completed in July 2019.
Key Takeaways of the Global BipolarDisorder Treatment Market:
The global bipolar disordertreatment market is expected to exhibit a CAGR of 5.2% over the forecastperiod, owing to increasing product launches and approvals, and high prevalenceof bipolar disorder. According to South African Depression & Anxiety Grouppublished in 2017, the life time prevalence of depression in South Africa isestimated to be 9.7%, which accounted for 4.5 million patients. Moreover,according to the same source, bipolar disorder affects 1% of population inSouth Africa.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/bipolar-disorders-treatment-market-2605
Among drug class, antipsychoticssegment held the largest market share in 2018, owing to increased prevalence ofbipolar disorder. According to the National Alliance on Mental IllnessFactsheet, September 2019, the annual prevalence of bipolar disorder in theU.S. was estimated at around 7 million.
Among distribution channel,retail pharmacies segment held the largest market share in 2018, owing topatients’ preference to buy products through retail pharmacies and increasingnumber of retail or independent pharmacies. According to PLOS Journal, August2017 findings, the number of independent pharmacies in the U.S. exhibited 3.8%growth from 22,737 (2007) to 23,596 (2015).
Companies operating in the globalbipolar disorder treatment market include Takeda Pharmaceutical CompanyLimited, Pfizer, Inc., Allergan plc, Otsuka Holdings Co. Ltd., Johnson &Johnson, Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca Plc, NovartisInternational AG, AbbVie Inc., H. Lundbeck A/S, Minerva Neurosciences, SumitomoDainippon Pharma Co., Ltd., Intra-Cellular Therapies Inc., Gedeon Richter Plc.,and Indivior PLC.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2605
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
